annual EBITDA:
-$265.77M+$60.47M(+18.54%)Summary
- As of today (June 18, 2025), TVTX annual EBITDA is -$265.77 million, with the most recent change of +$60.47 million (+18.54%) on December 31, 2024.
- During the last 3 years, TVTX annual EBITDA has fallen by -$81.32 million (-44.09%).
- TVTX annual EBITDA is now -309.92% below its all-time high of $126.61 million, reached on December 31, 2015.
Performance
TVTX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly EBITDA:
-$25.53M+$19.90M(+43.81%)Summary
- As of today (June 18, 2025), TVTX quarterly EBITDA is -$25.53 million, with the most recent change of +$19.90 million (+43.81%) on March 31, 2025.
- Over the past year, TVTX quarterly EBITDA has increased by +$97.56 million (+79.26%).
- TVTX quarterly EBITDA is now -117.14% below its all-time high of $148.91 million, reached on September 30, 2015.
Performance
TVTX quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
-$168.21M+$97.56M(+36.71%)Summary
- As of today (June 18, 2025), TVTX TTM EBITDA is -$168.21 million, with the most recent change of +$97.56 million (+36.71%) on March 31, 2025.
- Over the past year, TVTX TTM EBITDA has increased by +$194.10 million (+53.57%).
- TVTX TTM EBITDA is now -222.87% below its all-time high of $136.91 million, reached on September 30, 2015.
Performance
TVTX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
TVTX EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +18.5% | +79.3% | +53.6% |
| 3 y3 years | -44.1% | +61.5% | +16.2% |
| 5 y5 years | -147.9% | -234.8% | -100.2% |
TVTX EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -44.1% | +18.5% | at high | +79.3% | at high | +53.6% |
| 5 y | 5-year | -147.9% | +18.5% | -234.8% | +79.3% | -206.9% | +53.6% |
| alltime | all time | -309.9% | +18.5% | -117.1% | +79.3% | -222.9% | +53.6% |
TVTX EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2025 | - | -$25.53M(-43.8%) | -$168.21M(-36.7%) |
| Dec 2024 | -$265.77M(-18.5%) | -$45.43M(+11.3%) | -$265.77M(-10.4%) |
| Sep 2024 | - | -$40.82M(-27.7%) | -$296.56M(-10.3%) |
| Jun 2024 | - | -$56.43M(-54.2%) | -$330.67M(-8.7%) |
| Mar 2024 | - | -$123.09M(+61.5%) | -$362.32M(+11.1%) |
| Dec 2023 | -$326.25M(+9.0%) | -$76.22M(+1.7%) | -$326.25M(-0.1%) |
| Sep 2023 | - | -$74.93M(-14.9%) | -$326.43M(-1.9%) |
| Jun 2023 | - | -$88.08M(+1.2%) | -$332.58M(+10.7%) |
| Mar 2023 | - | -$87.02M(+13.9%) | -$300.41M(+7.4%) |
| Dec 2022 | -$299.42M(+62.3%) | -$76.40M(-5.8%) | -$279.70M(-2.7%) |
| Sep 2022 | - | -$81.09M(+45.1%) | -$287.46M(+25.4%) |
| Jun 2022 | - | -$55.90M(-15.7%) | -$229.19M(+14.1%) |
| Mar 2022 | - | -$66.31M(-21.2%) | -$200.79M(+13.7%) |
| Dec 2021 | -$184.46M(+27.1%) | -$84.16M(+268.7%) | -$176.63M(-13.1%) |
| Sep 2021 | - | -$22.82M(-17.0%) | -$203.17M(+6.0%) |
| Jun 2021 | - | -$27.49M(-34.8%) | -$191.67M(+6.7%) |
| Mar 2021 | - | -$42.16M(-61.9%) | -$179.69M(+23.8%) |
| Dec 2020 | -$145.16M(+35.4%) | -$110.70M(+877.9%) | -$145.16M(+164.9%) |
| Sep 2020 | - | -$11.32M(-27.1%) | -$54.80M(-22.3%) |
| Jun 2020 | - | -$15.52M(+103.5%) | -$70.57M(-16.0%) |
| Mar 2020 | - | -$7.63M(-62.5%) | -$84.03M(-21.6%) |
| Dec 2019 | -$107.21M(+46.1%) | -$20.34M(-24.9%) | -$107.21M(+26.9%) |
| Sep 2019 | - | -$27.09M(-6.5%) | -$84.49M(-18.9%) |
| Jun 2019 | - | -$28.97M(-6.0%) | -$104.17M(+13.7%) |
| Mar 2019 | - | -$30.81M(-1391.3%) | -$91.66M(+24.7%) |
| Dec 2018 | -$73.39M(+103.1%) | $2.39M(-105.1%) | -$73.49M(-9.6%) |
| Sep 2018 | - | -$46.77M(+184.1%) | -$81.34M(+68.4%) |
| Jun 2018 | - | -$16.46M(+30.2%) | -$48.31M(+15.3%) |
| Mar 2018 | - | -$12.65M(+131.5%) | -$41.91M(+10.3%) |
| Dec 2017 | -$36.14M | -$5.46M(-60.2%) | -$38.00M(+4.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2017 | - | -$13.74M(+36.6%) | -$36.52M(-25.5%) |
| Jun 2017 | - | -$10.06M(+15.1%) | -$49.03M(-11.9%) |
| Mar 2017 | - | -$8.74M(+119.5%) | -$55.65M(+51.6%) |
| Dec 2016 | -$36.71M(-129.0%) | -$3.98M(-84.8%) | -$36.71M(-11.4%) |
| Sep 2016 | - | -$26.25M(+57.4%) | -$41.42M(-131.0%) |
| Jun 2016 | - | -$16.68M(-263.5%) | $133.75M(+1.6%) |
| Mar 2016 | - | $10.20M(-217.4%) | $131.60M(+3.9%) |
| Dec 2015 | $126.61M(-270.2%) | -$8.69M(-105.8%) | $126.61M(-7.5%) |
| Sep 2015 | - | $148.91M(-890.7%) | $136.91M(-636.7%) |
| Jun 2015 | - | -$18.83M(-461.4%) | -$25.51M(-501.9%) |
| Mar 2015 | - | $5.21M(+223.1%) | $6.35M(-130.5%) |
| Dec 2014 | -$74.41M(+203.0%) | $1.61M(-111.9%) | -$20.80M(-21.5%) |
| Sep 2014 | - | -$13.50M(-203.7%) | -$26.48M(+46.5%) |
| Jun 2014 | - | $13.02M(-159.4%) | -$18.08M(-50.0%) |
| Mar 2014 | - | -$21.93M(+439.1%) | -$36.15M(+125.2%) |
| Dec 2013 | -$24.56M(-18.5%) | -$4.07M(-20.2%) | -$16.05M(+33.9%) |
| Sep 2013 | - | -$5.10M(+1.1%) | -$11.98M(+74.0%) |
| Jun 2013 | - | -$5.05M(+175.3%) | -$6.89M(+273.7%) |
| Mar 2013 | - | -$1.83M(>+9900.0%) | -$1.84M(>+9900.0%) |
| Dec 2012 | -$30.13M(>+9900.0%) | - | - |
| Nov 2012 | - | -$3200.00(+6.7%) | -$13.00K(+1.6%) |
| Aug 2012 | - | -$3000.00(0.0%) | -$12.80K(0.0%) |
| May 2012 | - | -$3000.00(-21.1%) | -$12.80K(0.0%) |
| Feb 2012 | - | -$3800.00(+26.7%) | -$12.80K(+1.6%) |
| Feb 2012 | -$12.80K(+0.8%) | - | - |
| Nov 2011 | - | -$3000.00(0.0%) | -$12.60K(-0.8%) |
| Aug 2011 | - | -$3000.00(0.0%) | -$12.70K(+30.9%) |
| May 2011 | - | -$3000.00(-16.7%) | -$9700.00(+44.8%) |
| Feb 2011 | -$12.70K | -$3600.00(+16.1%) | -$6700.00(+116.1%) |
| Nov 2010 | - | -$3100.00 | -$3100.00 |
FAQ
- What is Travere Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Travere Therapeutics?
- What is Travere Therapeutics annual EBITDA year-on-year change?
- What is Travere Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Travere Therapeutics?
- What is Travere Therapeutics quarterly EBITDA year-on-year change?
- What is Travere Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Travere Therapeutics?
- What is Travere Therapeutics TTM EBITDA year-on-year change?
What is Travere Therapeutics annual EBITDA?
The current annual EBITDA of TVTX is -$265.77M
What is the all time high annual EBITDA for Travere Therapeutics?
Travere Therapeutics all-time high annual EBITDA is $126.61M
What is Travere Therapeutics annual EBITDA year-on-year change?
Over the past year, TVTX annual EBITDA has changed by +$60.47M (+18.54%)
What is Travere Therapeutics quarterly EBITDA?
The current quarterly EBITDA of TVTX is -$25.53M
What is the all time high quarterly EBITDA for Travere Therapeutics?
Travere Therapeutics all-time high quarterly EBITDA is $148.91M
What is Travere Therapeutics quarterly EBITDA year-on-year change?
Over the past year, TVTX quarterly EBITDA has changed by +$97.56M (+79.26%)
What is Travere Therapeutics TTM EBITDA?
The current TTM EBITDA of TVTX is -$168.21M
What is the all time high TTM EBITDA for Travere Therapeutics?
Travere Therapeutics all-time high TTM EBITDA is $136.91M
What is Travere Therapeutics TTM EBITDA year-on-year change?
Over the past year, TVTX TTM EBITDA has changed by +$194.10M (+53.57%)